Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

e-Poster Display Session

225P - Prostate cancer treatments and outcomes in the elderly: A retrospective analysis of an Australian real-world cohort

Date

22 Nov 2020

Session

e-Poster Display Session

Topics

Tumour Site

Prostate Cancer

Presenters

Michael Fernando

Citation

Annals of Oncology (2020) 31 (suppl_6): S1325-S1333. 10.1016/annonc/annonc369

Authors

M. Fernando1, S. Wong2, J. Shapiro3, A.J. Weickhardt4, L. Spain5, A.A. Azad6, E. Kwan7, A. Muthasamy4, J. Torres8, P. Parente9, F.X. Parnis10, J.C.H. Goh11, P. Gibbs12, B. Tran6, A. Anton1

Author affiliations

  • 1 Oncology Department, Eastern Health, 3128 - Melbourne/AU
  • 2 Medical Oncology, Sunshine Hospital, 3021 - St Albans/AU
  • 3 Medical Oncology, Alfred Hospital, 3004 - Melbourne/AU
  • 4 Medical Oncology Dept, Olivia Newton-John Cancer Wellness & Research Centre, 3084 - Heidelberg/AU
  • 5 Medical Oncology, Eastern Health - Box Hill Hospital - Building B, 3128 - Box Hill/AU
  • 6 Medical Oncology Department, Peter MacCallum Cancer Centre, 3000 - Melbourne/AU
  • 7 Oncology, Monash Medical Centre, 3168 - Clayton/AU
  • 8 Oncology, Goulburn Valley Health, , Shepparton/AU
  • 9 Medical Oncology, Box Hill Hospital-Eastern health, 3128 - Box Hill/AU
  • 10 Medical Oncology, Adelaide Cancer Centre, 5037 - Adelaide/AU
  • 11 Medical Oncology, Royal Brisbane and Women's Hospital, 4029 - Herston/AU
  • 12 Oncology, Walter and Eliza Hall, Melbourne/AU

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 225P

Background

Elderly men (>/=75yo) comprise 25% of patients with prostate cancer. However, they are typically underrepresented in pivotal trials. Limited data suggest these patients receive less intensive treatment with greater toxicity, despite comparable response rates. Our retrospective study examined treatment patterns and outcomes in a real-world population with castration-resistant prostate cancer (CRPC).

Methods

Using the multi-centre electronic CRPC Australian Database (ePAD), we extracted clinicopathologic, treatment and outcome data. Descriptive statistics were used to report data in patients aged >/=75yo and <75yo. Comparisons between these groups were analysed using T-tests and Fisher’s exact tests. Time-to-event analyses were performed using the Kaplan-Meier method.

Results

We identified 753 men with CRPC, with 327 (43%) aged >/=75yo. Elderly patients had higher rates of ischemic heart disease (33% vs 16% in younger patients, p=0.004) and stroke (11% vs 5%, p=0.007). They were more likely to receive only one line of systemic therapy (67% vs 40%, p<0.001), and androgen receptor signalling inhibitors (ARSIs) were most commonly prescribed as initial therapy (78% vs 48%, p<0.001). Enrolment in clinical trials was less frequent (5% vs 15%, p<0.001). There was no statistical difference in treatment duration or PSA50 response rates with ARSIs or docetaxel (Table). Overall, serious adverse events (SAEs) leading to hospitalisation, dose delays or modifications occurred in more elderly men (24% vs 16%, p=0.003), with a trend towards greater SAEs in those receiving docetaxel or ARSIs. Elderly patients were more likely to stop docetaxel due to toxicity (39% vs 21%, p=0.02). Table: 225P

First-line therapy for CRPC

<75yrs >/=75years p-value
Abiraterone N=58 N=84
PSA50 response rate 24 (41%) 43 (51%) 0.30
Treatment duration 11.9 months 10.6 months 0.52
Serious adverse event 10 (17%) 24 (29%) 0.16
Cessation due to toxicity 6 (10%) 12 (14%) 0.61
Enzalutamide N=119 N=159
PSA50 response rate 63 (53%) 94 (59%) 0.33
Treatment duration 11.5 months 11.5 months 0.87
Serious adverse event 20 (17%) 36 (23%) 0.29
Cessation due to toxicity 8 (7%) 16 (10%) 0.39
Docetaxel N=155 N=41
PSA50 response rate 79 (51%) 18 (44%) 0.48
Treatment duration 6.0 months 4.6 months 0.24
Serious adverse event 28 (18%) 10 (24%) 0.38
Cessation due to toxicity 32 (21%) 16 (39%) 0.02
.

Conclusions

In our real-world cohort, elderly men had greater comorbidities and received fewer lines of systemic therapy. Although there was no difference in treatment response or duration, elderly patients experienced higher SAE rates. Prospective studies are required to further evaluate long-term outcomes in these patients.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Astellas, AstraZeneca, Janssen, Amgen.

Disclosure

E. Kwan: Honoraria (self): Janssen; Honoraria (self), Travel/Accommodation/Expenses: Ipsen; Research grant/Funding (institution), Travel/Accommodation/Expenses: Astellas; Research grant/Funding (institution), Travel/Accommodation/Expenses: Pfizer; Research grant/Funding (institution): AstraZeneca; Research grant/Funding (institution): Bristol-Myers Squibb; Research grant/Funding (institution): Merck Serono. F.X. Parnis: Leadership role, Administrative Board: Janssen; Leadership role, Administrative Board: Astellas; Leadership role, Administrative Board: Bayer. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.